Joshua Blake, NP
Family · Colorado Springs, CONPI 1104593102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Scilex Pharmaceuticals Inc. at 33.5% of the total. Reporting peaked in 2021 at $188 and has fallen 89.4% since, to $20 in 2024.
Across 16 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scilex Pharmaceuticals Inc.$87
- AbbVie$53
- Neurocrine Biosciences, Inc.$46
- Collegium Pharmaceutical, Inc.$29
- Globus Medical$20
- Biodelivery Sciences International, Inc.$12
- plus $12 from 1 others
What the payments were for
- Food & beverage$260100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Scilex Pharmaceuticals Inc. | 5 | $87 |
| AbbVie | 3 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Globus Medical | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Bioventus LLC | 1 | $12 |
How this compares
$260 in reported general payments places this provider in the 55th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 28 | $1,301 |
| Atorvastatin Calcium | 52 | $691 |
| Omeprazole | 33 | $668 |
| Rosuvastatin Calcium | 29 | $460 |
| Levothyroxine Sodium | 46 | $410 |
| Finasteride | 17 | $407 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $349 |
| Trazodone Hcl | 15 | $326 |
| Metoprolol Succinate | 20 | $278 |
| Tizanidine Hcl | 21 | $272 |
| Lisinopril | 23 | $214 |
| Amlodipine Besylate | 27 | $206 |
| Hydroxyzine Hcl | 17 | $178 |
| Losartan Potassium | 17 | $171 |
| Montelukast Sodium | 11 | $164 |
Paid to pharmacies, not to this prescriber.
Other family in Colorado Springs
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- Jeannette LillerColorado Springs$74K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Barbara ChamnessColorado Springs$15K
- Julie UnruhColorado Springs$14K
- Lisa HutchcraftColorado Springs$13K
- Kristin SekelskyColorado Springs$10K
- Leandrea TzitzicasColorado Springs$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.